Knights of Columbus Asset Advisors’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-5,476
Closed -$79.2K 405
2026
Q1
$79.2K Hold
5,476
﹤0.01% 369
2025
Q4
$78K Sell
5,476
-525
-9% -$5.16K ﹤0.01% 366
2025
Q3
$47.3K Buy
6,001
+159
+3% +$1.13K ﹤0.01% 354
2025
Q2
$33.5K Hold
5,842
﹤0.01% 345
2025
Q1
$47.7K Hold
5,842
﹤0.01% 330
2024
Q4
$55K Sell
5,842
-389
-6% -$4.04K ﹤0.01% 335
2024
Q3
$66.5K Buy
+6,231
New +$67.9K ﹤0.01% 345
2021
Q2
Sell
-95,709
Closed -$946K 318
2021
Q1
$946K Buy
95,709
+15,038
+19% +$233K 0.09% 245
2020
Q4
$1.86M Sell
80,671
-150
-0.2% -$3.07K 0.2% 183
2020
Q3
$1.14M Buy
80,821
+52,494
+185% +$765K 0.14% 223
2020
Q2
$427K Buy
+28,327
New +$345K 0.05% 279

Other funds holding FOLD

Knights of Columbus Asset Advisors's FOLD Position: Q2 2026 in Review

Knights of Columbus Asset Advisors sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 5,476 shares — an estimated $79.2K sold.

Knights of Columbus Asset Advisors first reported a position in FOLD in Q2 2020 and held it in 11 quarters. The position peaked at $1.86M in Q4 2020. 1 fund tracked by Wall St. Rank holds FOLD as of Q2 2026.

  • Knights of Columbus Asset Advisors reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Knights of Columbus Asset Advisors sold 5,476 Amicus Therapeutics shares in Q2 2026, an estimated $79.2K.
  • Knights of Columbus Asset Advisors first reported a position in Amicus Therapeutics in Q2 2020 and held it in 11 quarters.
  • Knights of Columbus Asset Advisors's Amicus Therapeutics position peaked at $1.86M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.